EMA Authorised: Saphnelo (anifrolumab) — AstraZeneca AB

View source ↗

Summary

The European Medicines Agency authorised Saphnelo (anifrolumab) for systemic lupus erythematosus, expanding EU treatment options. The marketing authorisation ho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• SAPHNELO (ANIFROLUMAB-FNIA)

Snippet

Status: Authorised. Therapeutic area: Lupus Erythematosus, Systemic. MAH: AstraZeneca AB. Decision date: 28/01/2026